This presentation will include a thorough review of the literature and remaining controversies in terms of anticoagulation for cancer-associated venous thromboembolism (VTE), from historical data of warfarin versus low molecular weight heparin to more recent landmark direct oral anticoagulants trials. This data will be supplemented by a discussion on pharmacologic properties and clinical pearls of anticoagulants, in addition to considerations for special populations. Ultimately, the presentation will discuss how to apply the literature to select the optimal anticoagulant for cancer-associated VTE, considering both patient and disease-specific characteristics.
- Provider:Horizon CME, Inc.
- Activity Link: http://default/node/1334
- Start Date: 2024-02-05 06:00:00
- End Date: 2024-02-05 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.25 hours
- Commercial Support: Source: BMS - Amount: 1785.0 - Is Kind Support: False Source: Merck - Amount: 1785.0 - Is Kind Support: False Source: Novocure - Amount: 1785.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest